¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"First and second branchial arch syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • morning glory syndrome
    ³ªÆÈ²ÉÁõÈıº
  • motor syndrome
    ¿îµ¿(ÁßÃß)ÁõÈıº
  • mucocutaneous lymph node syndrome
    Á¡¾×ÇǺθ²ÇÁÀýÁõÈıº
  • myasthenic syndrome
    ±Ù(À°)¹«·ÂÁõÈıº
  • Mallory-Weiss syndrome
    ¸»·Î¸®-¹ÙÀ̽ºÁõÈıº
  • myelodysplastic syndrome
    °ñ¼öÇü¼ºÀÌ»óÁõÈıº
  • myeloproliferative syndrome
    °ñ¼öÁõ½ÄÁõÈıº
  • myofascial pain syndrome
    ±Ù¸·ÅëÁõÁõÈıº
  • myofascial pain-dysfunction syndrome
    ±Ù¸·ÅëÁõ±â´ÉÀå¾ÖÁõÈıº
  • Marfan syndrome
    ¸¶¸£ÆÎÁõÈıº
  • maternal deprivation syndrome
    ¸ð¼º¹ÚÅ»ÁõÈıº
  • McCune-Albright syndrome
    ¸ÆÄï-¿Ãºê¶óÀÌÆ®ÁõÈıº
  • meconium plug syndrome
    ꝏ¶°³ÁõÈıº
  • megacystis-megaureter syndrome
    °Å´ë¹æ±¤°Å´ë¿ä°üÁõÈıº
  • Meigs¡¯ syndrome
    ¸ÞÀ̱×ÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
  • neurovascular syndrome
    ½Å°æÇ÷°üÁõÈıº
  • neurovisceral syndrome
    ½Å°æ³»ÀåÁõÈıº
  • nutritional deficiency syndrome
    ¿µ¾ç°áÇÌÁõÈıº
  • obstructive sleep apnea syndrome
    Æó¼â¼ö¸é¹«È£ÈíÁõÈıº
  • oculoauriculovertebral syndrome
    ´«±Ó¹ÙÄûôÃßÁõÈıº
  • oral-facial-digital syndrome
    ÀÔ¾ó±¼¼Õ°¡¶ôÁõÈıº, ±¸°­¾È¸é¼öÁ·ÁöÁõÈıº
  • orbital apex syndrome
    ´«È®²ÀÁöÁõÈıº
  • organic brain syndrome
    ±âÁú³úÁõÈıº
  • organic mental syndrome
    ±âÁúÁ¤½ÅÁõÈıº
  • otocraniocephalic syndrome
    ±Í¸Ó¸®ÁõÈıº, À̵ΰ³ÁõÈıº
  • overlap syndrome
    °ãħÁõÈıº, ÁßøÁõÈıº
  • overwear syndrome
    °úµµÂø¿ëÁõÈıº
  • preleukemia myelodysplastic syndrome
    °ñ¼öÇü¼ºÀÌ»óÁõÈıº
  • pancoast syndrome
    ÆÇÄÚ½ºÆ®ÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • Loeffler s eosinophilic syndrome
    ·ÚÇ÷¯È£»ê±¸ÁõÈıº.
  • Loefflers syndrome
    ·ÚÇ÷¯ÁõÈıº
  • Lofgrens syndrome
    ·ÚÇÁ ±×¸° ÁõÈıº
  • Marchesanis syndrome
    ¸¶¸£ÄÉ»ç´ÏÁõÈıº
  • Marcus-Gunn syndrome
    ¸¶¸£Äí½º-°ÇÁõÈıº
  • Marfan s syndrome
    ¸¶¸£ÆÎÁõÈıº
  • Marfan s syndrome
    ¸¶¸£ÆÎÁõÈıº.
  • Marfans syndrome
    ¸¶¸£ÆÎÁõÈıº.
  • Marfans syndrome
    ¸¶¸£ÆÎ ÁõÈıº.
  • McLeod syndrome
    ¸Æ·¹¿ÀÁõÈıº
  • Melkersson-Rosenthal syndrome
    ¸áÄ¿½¼ ·ÎÁ¨Å» ÁõÈıº
  • Meniere s syndrome
    ¸Þ´Ï¿¡¸£ÁõÈıº.
  • Menieres syndrome
    ¸Þ´Ï¿¡¸£ÁõÈıº
  • Menkes (kinky) hair syndrome
    ¸àÄɾûÅ´ÅÐ ÁõÈıº
  • Menkes kinky hair syndrome
    ¸àÄÉŲ۸ðÁõÈıº
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • maxillary arch
    »ó¾Ç±Ã(ß¾äÉÏá).
  • milk dental arch
    À¯Ä¡¿­±Ã(êáöÍæêÏá).
  • mixed dental arch
    È¥ÇÕÄ¡¿­°æ.
  • narrow dental arch
    ÇùÂøÄ¡¿­±Ã(úõó¸öÍæêÏá).
  • neural arch
    ½Å°æ?ãêÌèÏá).
  • neural arch fissure
    ôÃß»À°í¸®Æ´»õ
  • node of arch of azygous vein
    (ȦÁ¤¸ÆÈ°¸²ÇÁÀý)
  • oral arch
    ±¸°³±Ã, ÀÔ±Ã
  • oral arch
    ÀÔ±Ã, ±¸°³±Ã(Ï¢ËÏÏá).
  • palate, arch of
    ±¸°³±Ã
  • palatoglossal arch
    ±¸°³¼³±Ã, ±¸°³Çô±Ã{ÇØ}
  • palatoglossal arch
    ÀÔõÀåÇôȰ
  • palatoglossal arch ³ª arcus palatoglossus
    ±¸°³¼³±Ã(Ï¢ËÏàßÏá).
  • palatopharyngeal arch
    ÀÔõÀåÀεÎȰ
  • palpebral arch
    ¾È°Ë±Ã(äÑÌ¡Ïá)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
FDI first dorsal interosseous [muscle]; International Dental Federation [Federation Dentaire Internation...
FDLMP first day of last menstrual period
FMN first malignant neoplasm; flavin mononucleotide; frontomaxillonasal [suture]
FMP faculty mentorship program; first menstrual period; fructose monophosphate
FMU first morning urine
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
BRBNS Blue Rubber Bleb Nevus Syndrome
BDLS Brachmann-De Lange syndrome
BOS Bronchiolitis Obliterans Syndrome
BCS Budd Chiari syndrome
BMS Burning Mouth Syndrome
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • carotid sinus syndrome
    °æµ¿¸Æµ¿ ÁõÈıº
  • carpal tunnel syndrome
    ¼ö±Ù°ü ÁõÈıº, ÆÈ¸ñ ÅͳΠÁõÈıº
    1. ¼Õ°¡¶ôÀ» Á¶ÀýÇÏ´Â Àδ븦 µÑ·¯½Î´Â Ȱ¸·ÀÌ ÀÚ±ØÀ» ¹Þ°Å³ª ¿°ÁõÀÌ »ý±ä °Í. ÆÈ¸ñ ÅͳΠÁõÈıºÀº ¼ÕÀ¸·Î ÀÛ¾÷À» ÇÏ´Â »ç¶÷µé ƯÈ÷ °Ç¹Ý ¾Ç±â¸¦ ¿¬ÁÖ°¡, ŸÀÚ¼ö ±×¸®°í ÀÚ·á °ü¸®ÀÚ µî°ú °°Àº »ç¶÷¿¡°Ô Àå¾Ö°¡ ¹ß»ýÇÑ´Ù. 2. ¼ö±Ù°ü³» Á¤Áß ½Å°æÀÌ ¾Ð¹ÚµÉ ¶§ ÀϾ´Â ÁõÈıºÀ¸·Î¼­, ¼Õ°¡¶ôÀÇ µ¿Åë, ÀÛ¿­°¨ ±×¸®°í ÀÌ»ó °¨°¢À» µ¿¹ÝÇϸç, ¶§·Î´Â ÆÈ²ÞÄ¡±îÁö ÆÄ±ÞµÈ´Ù. 3. ¼ö±Ù°üÀº ¼Õ¸ñÀÇ ¼öÀåºÎ¿¡ À§Ä¡Çϸç, ¹èÃø°ú Ãøº®Àº ¼ö±Ù°ñ·Î ±¸¼ºµÇ°í, º¹ÃøÀº ´Ü´ÜÇÑ ¼¶À¯¼º Ⱦ¼ö±Ù Àδë·Î µ¤Çô ÅͳÎÀ» Çü¼ºÇÑ´Ù. Åͳγ»¿¡´Â Á¤Áß ½Å°æ, õÁö±¼±Ù, ½ÉÁö±¼±Ù, À幫Áö±¼±ÙÀÌ Åë°úÇϴµ¥ Á¤Áß ½Å°æÀÇ ¾Ð¹ÚÀ¸·Î ¹ß»ýÇÏ´Â ÁõÈıºÀÌ´Ù.
  • Carpenter syndrome
    Ä«¾ÆÆæÅÍ ÁõÈıº
    ÷µÎ, ´ÙÁö ÇÕÁöÁõ, ´ÜÁöÁõ, ÀÌ»ó ¾È¸é, ºñ¸¸Áõ, Áö´ÉÀúÇÏ, ¼º¼± ±â´É ºÎÀüÀ» µ¿¹ÝÇÏ´Â »ó¿°»öü ¿­¼º À¯Àü¼º ÁõÈıº.
  • cartoid sinus syndrome
    °æµ¿¸Æµ¿ ÁõÈıº
  • catcry syndrome
    ¹¦¼º ÁõÈıº
  • cauda equina syndrome
    ¸¶¹Ì ÁõÈıº
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¼º ¸é¿ª °áÇÌ ÁõÈıº
  • cerebrohepatorenal syndrome
    ³ú°£ ½Å ÁõÈıº
  • cervical fusion syndrome
    °æºÎ À¯ÇÕ ÁõÈıº
  • cervicobrachial syndrome
    °æ »ó¿Ï ÁõÈıº
  • Cestans syndrome
    ¼¼½ºÅº ÁõÈıº
  • Charcot-Wilbrand syndrome
    »þ¸£ÄÚ-ºôºê¶õµå ÁõÈıº
  • chiasmal syndrome
    ½Ã ½Å°æ ±³Â÷ºÎ ÁõÈıº
  • Chilaiditis syndrome
    ų¶óÀÌµðÆ¼ ÁõÈıº
    °áÀå ¶Ç´Â ¼ÒÀåÀÇ ÀϺΰ¡ °£°ú Ⱦ°æ¸· »çÀÌ¿¡ °¨µ·ÇÏ¿© ÀϾ´Â ÁõÈıº.
  • cholecysto-hepatic flexure adhesion syndrome
    ´ã³¶ °áÀå °£°îºÎ À¯Âø ÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
magnesia and alumina oral suspension A mixture of magnesium hydroxide and variable amounts of aluminum oxide; used as an antacid.
(05 Mar 2000)
maintenance and engineering, hospital Hospital department whose primary function is the upkeep and supervision of the buildings and grounds and the maintenance of hospital physical plant and equipment which requires engineering expertise.
(12 Dec 1998)
P and P test A test formerly used by some to control anticoagulant therapy with bishydroxycoumarin and indandione drugs.
Synonym: P and P test.
(05 Mar 2000)
malignancy and immunodeficiency <radiology> High risk of malignancy (especially lymphoma/leukaemia, GI tumours): X-linked agammaglobulinaemia (Bruton's), common variable immunodeficiency, severe combined immunodeficiency (SCID kids), ataxia-telangectasia, Wiscott-Aldrich syndrome, selective IgA deficiency
(12 Dec 1998)
Gell and Coombs Classification A classification system that differentiates the 4 types of hypersensitivity reactions: Type I: anaphylactic reactions, Type II: cytotoxic reactions, Type III: immune complex reactions, and Type IV: cell-mediated reactions.
(05 Mar 2000)
rate setting and review A method of examining and setting levels of payments.
(12 Dec 1998)
ratio of decayed and filled surfaces An index of decayed and filled permanent surfaces per person, per full complement of 122 tooth surfaces.
(05 Mar 2000)
ratio of decayed and filled teeth An index of decayed and filled permanent teeth per person, per full complement of 28 teeth.
(05 Mar 2000)
receptors, cytoplasmic and nuclear Proteins in the cytoplasm or nucleus that specifically bind signalling molecules and trigger changes which influence the behaviour of cells. The major groups are the steroid hormone receptors, which usually are found in the cytoplasm, and the thyroid hormone receptors, which usually are found in the nucleus. Receptors, unlike enzymes, generally do not catalyze chemical changes in their ligands.
(12 Dec 1998)
maternal age 35 and over Pregnancy in women 35 or more years of age. It is used for normal pregnancies and for problems of pregnancy occurring in a woman's late reproductive years. These include effects on the mother's physical and mental health as well as risks of perinatal mortality and foetal abnormality.
(12 Dec 1998)
VH and VL genes/domains VH and VL genes define in part the sequences of the variable heavy and light regions of immunoglobulin molecules. VH and VL domains are the regions of amino acid sequence so defined. J genes and, in the case of the heavy chain, a D gene (D=diversity) also define these regions. Gene rearrangement also plays a role in determining the sequences in which the genes are joined as the DNA of the immunoglobulin producing cell matures.
(18 Nov 1997)
referral and consultation The practice of sending a patient to another program or practitioner for services or advice which the referring source is not prepared to provide.
(12 Dec 1998)
measles, mumps and rubella vaccine A combination of live attenuated measles, mumps, and rubella viruses in an aqueous suspension; used for immunization against the respective diseases.
(05 Mar 2000)
rehabilitation of speech and language disorders Procedures for assisting a person with a speech or language disorder to communicate with maximum efficiency.
(12 Dec 1998)
patient credit and collection Accounting procedures for determining credit status and methods of obtaining payment.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á